Syngen Biotech Co.,Ltd. (TPEX:8279)
Taiwan · Delayed Price · Currency is TWD 80.30
-0.20 (-0.25%)
Nov 13, 2026, 1:30 PM CST
Syngen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,048 | 2,136 | 2,014 | 1,837 | 1,931 | 1,471 | |
Revenue Growth | -3.92% | 6.10% | 9.60% | -4.84% | 31.22% | 12.19% |
Cost of Revenue | 1,412 | 1,413 | 1,290 | 1,193 | 1,242 | 942.93 |
Gross Profit | 635.67 | 723.59 | 723.94 | 643.92 | 688.15 | 528.34 |
Selling, General & Admin | 325.75 | 339.07 | 354.38 | 302.88 | 262.63 | 197.02 |
Research & Development | 60.93 | 60.56 | 59.34 | 46.76 | 45.32 | 49.52 |
Operating Expenses | 386.8 | 396.61 | 420.64 | 341.06 | 325.78 | 246.86 |
Operating Income | 248.87 | 326.98 | 303.3 | 302.86 | 362.38 | 281.48 |
Interest Expense | -3.85 | -5.65 | -9.28 | -8.86 | -5.07 | -3.21 |
Interest & Investment Income | 1.78 | 2.38 | 2.05 | 1.43 | 0.61 | 0.32 |
Earnings From Equity Investments | 1.46 | 8.09 | -5.32 | 36.08 | 26.64 | 14.81 |
Currency Exchange Gain (Loss) | -0.32 | -0.32 | 5.32 | -1.93 | 10.29 | -4.31 |
Other Non Operating Income (Expenses) | 7.38 | 3.62 | 4.18 | 4.49 | 1.58 | 7.87 |
EBT Excluding Unusual Items | 255.33 | 335.09 | 300.25 | 334.07 | 396.42 | 296.95 |
Gain (Loss) on Sale of Investments | 0.3 | 0.3 | -0.49 | 0.02 | 0.21 | 0.98 |
Gain (Loss) on Sale of Assets | -0.15 | -0.15 | -0.15 | -0.28 | -0.21 | -0.63 |
Asset Writedown | -0.4 | -0.4 | - | - | - | -1.81 |
Pretax Income | 255.08 | 334.84 | 299.61 | 333.8 | 396.42 | 295.49 |
Income Tax Expense | 50.36 | 63.25 | 59.4 | 58.98 | 75.18 | 57.72 |
Net Income | 204.72 | 271.59 | 240.21 | 274.83 | 321.24 | 237.77 |
Net Income to Common | 204.72 | 271.59 | 240.21 | 274.83 | 321.24 | 237.77 |
Net Income Growth | -29.93% | 13.07% | -12.60% | -14.45% | 35.10% | 10.31% |
Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 27 | 27 |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 27 | 27 |
Shares Change | 0.06% | 0.02% | - | -0.01% | -0.00% | -0.01% |
EPS (Basic) | 7.56 | 10.02 | 8.86 | 10.14 | 11.85 | 8.77 |
EPS (Diluted) | 7.54 | 10.01 | 8.85 | 10.13 | 11.84 | 8.76 |
EPS Growth | -29.97% | 13.11% | -12.64% | -14.44% | 35.16% | 10.33% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 239.48 | 255.92 | 287.83 | 323.23 | -306.79 | 274.83 |
Free Cash Flow Per Share | 8.82 | 9.43 | 10.61 | 11.91 | -11.31 | 10.13 |
Dividend Per Share | - | 5.000 | 5.000 | 5.000 | 5.000 | 4.000 |
Dividend Growth | - | 0% | 0% | 0% | 25.00% | 14.29% |
Gross Margin | 31.04% | 33.87% | 35.95% | 35.05% | 35.64% | 35.91% |
Operating Margin | 12.15% | 15.30% | 15.06% | 16.48% | 18.77% | 19.13% |
Profit Margin | 10.00% | 12.71% | 11.93% | 14.96% | 16.64% | 16.16% |
Free Cash Flow Margin | 11.69% | 11.98% | 14.29% | 17.59% | -15.89% | 18.68% |
EBITDA | 347.22 | 431.71 | 402.1 | 386.21 | 432.93 | 347.82 |
EBITDA Margin | 16.95% | 20.21% | 19.97% | 21.02% | 22.43% | 23.64% |
D&A For EBITDA | 98.35 | 104.73 | 98.8 | 83.35 | 70.56 | 66.34 |
EBIT | 248.87 | 326.98 | 303.3 | 302.86 | 362.38 | 281.48 |
EBIT Margin | 12.15% | 15.30% | 15.06% | 16.48% | 18.77% | 19.13% |
Effective Tax Rate | 19.74% | 18.89% | 19.83% | 17.67% | 18.96% | 19.53% |